Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067748049> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2067748049 endingPage "62" @default.
- W2067748049 startingPage "49" @default.
- W2067748049 abstract "The effects of apomorphine (0.01 mg/kg SC) a direct-acting dopamine (DA) agonist, MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) (20 mg PO), a direct-acting serotonin (5-HT) agonist, and placebo on smooth pursuit eye movements were evaluated in 10 to 12 normal volunteers. Smooth pursuit was tested just prior to administration of either apomorphine, MK-212, or placebo (on separate days), and then repeatedly tested at 30 min intervals for two hours after dose administration. The smooth pursuit targets were a series of predictable, constant velocity ramps with velocities of 5°/sec (slow target) and 20°/sec (fast target). Eye movements were recorded with infrared oculography, and the following six measures were obtained; steady-state gain (slow-target-gain; fast-target-gain), corrective catch-up saccade (CUS) rate (slow-target-CUS-rate; fast-target-CUS-rate), and CUS amplitude (slow-target-CUS-amplitude; fast-target-CUS-amplitude). The placebo test yielded a statistically significant monotonic decrease over time in slow-target-gain and corresponding increase in slow-target-CUS-rate, but no effects of placebo were noted for the fast target. Apomorphine injection produced a marked reduction in both slow-target-gain and fast-target-gain at 30 min, returning to baseline thereafter. Apomorphine injection also produced a statistically significant increase in slow-target-CUS-amplitude. Ingestion of MK-212 produced a statistically significant increase in slow-target-gain and fast-target-gain as well as a corresponding decrease in slow-target-CUS-rate and fast-target-CUS-rate at 90 min or 120 min. There was evidence that the decline in slow-target-gain after apomorphine was associated with side-effects such as sleepiness, but the decline in fast-target-gain was not related to side-effects. The improved smooth pursuit performance after MK-212 was not related to side-effects. The data suggest that serotoninergic stimulation can improve smooth pursuit performance, whereas dopaminergic stimulation worsens this performance." @default.
- W2067748049 created "2016-06-24" @default.
- W2067748049 creator A5059121057 @default.
- W2067748049 creator A5060728653 @default.
- W2067748049 creator A5064814323 @default.
- W2067748049 date "1994-08-01" @default.
- W2067748049 modified "2023-09-27" @default.
- W2067748049 title "The Effect of Apomorphine, MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) and Placebo on Smooth Pursuit Gain and Corrective Saccades in Normal Subjects" @default.
- W2067748049 doi "https://doi.org/10.1038/npp.1994.35" @default.
- W2067748049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7945744" @default.
- W2067748049 hasPublicationYear "1994" @default.
- W2067748049 type Work @default.
- W2067748049 sameAs 2067748049 @default.
- W2067748049 citedByCount "12" @default.
- W2067748049 countsByYear W20677480492013 @default.
- W2067748049 countsByYear W20677480492019 @default.
- W2067748049 countsByYear W20677480492021 @default.
- W2067748049 crossrefType "journal-article" @default.
- W2067748049 hasAuthorship W2067748049A5059121057 @default.
- W2067748049 hasAuthorship W2067748049A5060728653 @default.
- W2067748049 hasAuthorship W2067748049A5064814323 @default.
- W2067748049 hasBestOaLocation W20677480491 @default.
- W2067748049 hasConcept C126322002 @default.
- W2067748049 hasConcept C134018914 @default.
- W2067748049 hasConcept C142724271 @default.
- W2067748049 hasConcept C170493617 @default.
- W2067748049 hasConcept C185592680 @default.
- W2067748049 hasConcept C204787440 @default.
- W2067748049 hasConcept C27081682 @default.
- W2067748049 hasConcept C2777525119 @default.
- W2067748049 hasConcept C2778258207 @default.
- W2067748049 hasConcept C2778938600 @default.
- W2067748049 hasConcept C42219234 @default.
- W2067748049 hasConcept C71924100 @default.
- W2067748049 hasConceptScore W2067748049C126322002 @default.
- W2067748049 hasConceptScore W2067748049C134018914 @default.
- W2067748049 hasConceptScore W2067748049C142724271 @default.
- W2067748049 hasConceptScore W2067748049C170493617 @default.
- W2067748049 hasConceptScore W2067748049C185592680 @default.
- W2067748049 hasConceptScore W2067748049C204787440 @default.
- W2067748049 hasConceptScore W2067748049C27081682 @default.
- W2067748049 hasConceptScore W2067748049C2777525119 @default.
- W2067748049 hasConceptScore W2067748049C2778258207 @default.
- W2067748049 hasConceptScore W2067748049C2778938600 @default.
- W2067748049 hasConceptScore W2067748049C42219234 @default.
- W2067748049 hasConceptScore W2067748049C71924100 @default.
- W2067748049 hasIssue "1" @default.
- W2067748049 hasLocation W20677480491 @default.
- W2067748049 hasLocation W20677480492 @default.
- W2067748049 hasOpenAccess W2067748049 @default.
- W2067748049 hasPrimaryLocation W20677480491 @default.
- W2067748049 hasRelatedWork W1970098290 @default.
- W2067748049 hasRelatedWork W1973409413 @default.
- W2067748049 hasRelatedWork W1980960450 @default.
- W2067748049 hasRelatedWork W1989499551 @default.
- W2067748049 hasRelatedWork W2043965189 @default.
- W2067748049 hasRelatedWork W2048474481 @default.
- W2067748049 hasRelatedWork W2054764534 @default.
- W2067748049 hasRelatedWork W2075374533 @default.
- W2067748049 hasRelatedWork W2114220190 @default.
- W2067748049 hasRelatedWork W2581412799 @default.
- W2067748049 hasVolume "11" @default.
- W2067748049 isParatext "false" @default.
- W2067748049 isRetracted "false" @default.
- W2067748049 magId "2067748049" @default.
- W2067748049 workType "article" @default.